Alzheimer's drug benefits 'too small' to offer on NHS, NICE finds
By Lee Peart 19 June 2025
The benefits from Alzheimer’s drugs donanemab and lecanemab are too small to justify the additional costs to the NHS, NICE has found.
Independent Reviewing Officer
£47,181 to £51,356 per annum
Selby, North Yorkshire£47,181 to £51,356 per annum
Independent Reviewing Officer
£47,181 to £51,356 per annum
Harrogate, North Yorkshire£47,181 to £51,356 per annum
Independent Reviewing Officer
£47,181 to £51,356 per annum
Scarborough, North Yorkshire£47,181 to £51,356 per annum
Most Read News
- NHS SBS awarded construction procurement Gold Standard
- Children and young people facing 'barbaric' A&E waits
- Staff felt trust was not safe before Calocane killings, inquiry hears
- Frontline productivity: a strategic imperative for NHS leaders
- Trust director admits 'missed opportunities' in care of Nottingham killer
Independent Reviewing Officer
£47,181 to £51,356 per annum
Selby, North Yorkshire£47,181 to £51,356 per annum
Independent Reviewing Officer
£47,181 to £51,356 per annum
Harrogate, North Yorkshire£47,181 to £51,356 per annum
Independent Reviewing Officer
£47,181 to £51,356 per annum
Scarborough, North Yorkshire£47,181 to £51,356 per annum
Most Read News
- NHS SBS awarded construction procurement Gold Standard
- Children and young people facing 'barbaric' A&E waits
- Staff felt trust was not safe before Calocane killings, inquiry hears
- Frontline productivity: a strategic imperative for NHS leaders
- Trust director admits 'missed opportunities' in care of Nottingham killer
©2026 Hemming Group Limited. Registered in England and Wales. Registered No: 490200. VAT number GB342 023 408
